Idaho is currently home to 356 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boise, Meridian, Idaho Falls and Nampa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
HEAL-IST IDE Trial
NCT05280093
Recruiting
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Saint Alphonsus Regional Medical Center, Boise, Idaho
Conditions: Inappropriate Sinus Tachycardia
Register for Updates
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
NCT05775523
Recruiting
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/02/2025
Locations: Ascendis Investigational Site, Boise, Idaho
Conditions: Growth Hormone Deficiency
Register for Updates
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
05/01/2025
Locations: Research Site 021, Meridian, Idaho
Conditions: COPD
Register for Updates
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT05896189
Recruiting
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/01/2025
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: Breast Cancer, Cognitive Impairments
Register for Updates
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
NCT05820672
Recruiting
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
05/01/2025
Locations: Ascendis Investigational Site, Boise, Idaho
Conditions: Growth Hormone Deficiency
Register for Updates
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673
Recruiting
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
05/01/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Register for Updates
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
NCT06720038
Recruiting
The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 3 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
04/30/2025
Locations: Clinical Research Prime, LLP, Idaho Falls, Idaho
Conditions: Pneumococcal Vaccines
Register for Updates
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
NCT03996265
Recruiting
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Saint Luke's Cancer Institute - Boise, Boise, Idaho
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
A Study to Evaluate Solriktug in Adult Participants With Asthma
NCT06496607
Recruiting
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/25/2025
Locations: Research Site 022, Meridian, Idaho
Conditions: Asthma
Register for Updates
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016
Recruiting
The Sponsor is developing a progestin-only contraceptive transdermal system (patch). The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated. The study patch is a transdermal system that contains the active ingredient, progestin.
Gender:
FEMALE
Ages:
16 years and above
Trial Updated:
04/15/2025
Locations: Leavitt ClinResearch, Idaho Falls, Idaho
Conditions: Female Contraception
Register for Updates
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076
Recruiting
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Leavitt Clinical Research, Idaho Falls, Idaho
Conditions: Plaque Psoriasis
Register for Updates
PREVENT ALL ALS Study
NCT06581861
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Saint Alphonsus Regional Medical Center, Boise, Idaho
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates